Published in J Virol on November 06, 2013
Replication-competent influenza A viruses expressing a red fluorescent protein. Virology (2014) 0.89
Cytomegalovirus-mediated activation of pyrimidine biosynthesis drives UDP-sugar synthesis to support viral protein glycosylation. Proc Natl Acad Sci U S A (2014) 0.85
Broad-spectrum antiviral agents. Front Microbiol (2015) 0.76
Reverse Genetics Approaches to Control Arenavirus. Methods Mol Biol (2016) 0.75
Reporter-Expressing, Replicating-Competent Recombinant Arenaviruses. Viruses (2016) 0.75
Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond. Nat Rev Drug Discov (2017) 0.75
An original chemical series of pyrimidine biosynthesis inhibitors that boost the antiviral interferon response. Antimicrob Agents Chemother (2017) 0.75
A new arenavirus in a cluster of fatal transplant-associated diseases. N Engl J Med (2008) 7.73
Lassa fever. Effective therapy with ribavirin. N Engl J Med (1986) 6.38
Systems-level metabolic flux profiling identifies fatty acid synthesis as a target for antiviral therapy. Nat Biotechnol (2008) 5.77
Transmission of lymphocytic choriomeningitis virus by organ transplantation. N Engl J Med (2006) 5.42
The small RING finger protein Z drives arenavirus budding: implications for antiviral strategies. Proc Natl Acad Sci U S A (2003) 3.34
Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction. Arch Biochem Biophys (1993) 3.26
Metabolomic analysis and visualization engine for LC-MS data. Anal Chem (2010) 2.77
NP and L proteins of lymphocytic choriomeningitis virus (LCMV) are sufficient for efficient transcription and replication of LCMV genomic RNA analogs. J Virol (2000) 2.74
Inhibition of the type I interferon response by the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus. J Virol (2006) 2.61
Lassa fever in the United States. Investigation of a case and new guidelines for management. N Engl J Med (1990) 2.57
Possession, use, and transfer of select agents and toxins; biennial review. Final rule. Fed Regist (2012) 2.54
Lassa virus. Crit Rev Clin Lab Sci (2004) 2.27
Mechanisms of action of ribavirin against distinct viruses. Rev Med Virol (2005) 2.00
Differential inhibition of type I interferon induction by arenavirus nucleoproteins. J Virol (2007) 1.95
Treatment of Argentine hemorrhagic fever. Antiviral Res (2007) 1.93
The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J Virol (2005) 1.91
Mammalian pyrimidine biosynthesis: fresh insights into an ancient pathway. J Biol Chem (2004) 1.86
Recovery of an arenavirus entirely from RNA polymerase I/II-driven cDNA. Proc Natl Acad Sci U S A (2006) 1.79
High-throughput screening for potent and selective inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. J Biol Chem (2005) 1.73
Generation of recombinant lymphocytic choriomeningitis viruses with trisegmented genomes stably expressing two additional genes of interest. Proc Natl Acad Sci U S A (2009) 1.72
Lymphocytic choriomeningitis virus. A neglected pathogen of man. Arch Pathol Lab Med (1992) 1.71
Role of the virus nucleoprotein in the regulation of lymphocytic choriomeningitis virus transcription and RNA replication. J Virol (2003) 1.69
Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. Antimicrob Agents Chemother (2000) 1.58
Lymphocytic choriomeningitis virus: an underdiagnosed cause of congenital chorioretinitis. Am J Ophthalmol (2000) 1.57
Viral hemorrhagic fever hazards for travelers in Africa. Clin Infect Dis (2001) 1.45
Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis. Proc Natl Acad Sci U S A (2011) 1.42
Malarial dihydroorotate dehydrogenase. Substrate and inhibitor specificity. J Biol Chem (2002) 1.29
Cell entry by human pathogenic arenaviruses. Cell Microbiol (2007) 1.25
Hematologic side effects of interferon and ribavirin therapy. J Clin Gastroenterol (2005) 1.20
Antiretroviral therapy for HIV infection: promises and problems. JAMA (1998) 1.16
Arenavirus nucleoproteins prevent activation of nuclear factor kappa B. J Virol (2012) 1.14
Arenavirus reverse genetics: new approaches for the investigation of arenavirus biology and development of antiviral strategies. Virology (2011) 1.10
Lassa virus nucleoprotein mutants generated by reverse genetics induce a robust type I interferon response in human dendritic cells and macrophages. J Virol (2011) 1.06
Uracil metabolism--UMP synthesis from orotic acid or uridine and conversion of uracil to beta-alanine: enzymes and cDNAs. Prog Nucleic Acid Res Mol Biol (1996) 1.04
Lymphocytic choriomeningitis virus: a neglected central nervous system pathogen. Clin Infect Dis (1996) 1.03
Ribavirin can be mutagenic for arenaviruses. J Virol (2011) 1.03
Use of single-cycle infectious lymphocytic choriomeningitis virus to study hemorrhagic fever arenaviruses. J Virol (2010) 1.03
Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives. Biochem Pharmacol (1998) 0.96
Molecular approaches for the treatment of hemorrhagic fever virus infections. Antiviral Res (1993) 0.95
Depletion of GTP pool is not the predominant mechanism by which ribavirin exerts its antiviral effect on Lassa virus. Antiviral Res (2011) 0.93
Inhibition of pyrimidine biosynthesis pathway suppresses viral growth through innate immunity. PLoS Pathog (2013) 0.93
Development of a new tacaribe arenavirus infection model and its use to explore antiviral activity of a novel aristeromycin analog. PLoS One (2010) 0.89
4SC-101, a novel small molecule dihydroorotate dehydrogenase inhibitor, suppresses systemic lupus erythematosus in MRL-(Fas)lpr mice. Am J Pathol (2010) 0.88
Ribavirin therapy for lassa fever. Practitioner (1988) 0.88
The PI3K/Akt pathway contributes to arenavirus budding. J Virol (2012) 0.87
Inhibition of Junin virus RNA synthesis by an antiviral acridone derivative. Antiviral Res (2011) 0.87
An update of teriflunomide for treatment of multiple sclerosis. Ther Clin Risk Manag (2013) 0.86
Antiviral effect of ribavirin on Junin virus replication in vitro. Rev Argent Microbiol (1986) 0.85
Arenavirus reverse genetics for vaccine development. J Gen Virol (2013) 0.83
Host cell factors as antiviral targets in arenavirus infection. Viruses (2012) 0.81
Sustained virologic response after therapy with the HCV protease inhibitor narlaprevir in combination with peginterferon and ribavirin is durable through long-term follow-up. J Viral Hepat (2013) 0.81
Inactivation of S-adenosyl-L-homocysteine hydrolase with novel 5'-thioadenosine derivatives. Antiviral effects. Bioorg Med Chem Lett (2003) 0.80
Combination of MEK inhibitors and oseltamivir leads to synergistic antiviral effects after influenza A virus infection in vitro. Antiviral Res (2013) 0.79
Arenaviruses and lethal mutagenesis. Prospects for new ribavirin-based interventions. Viruses (2012) 0.79
The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity (2011) 6.00
Human host factors required for influenza virus replication. Nature (2010) 5.28
Inhibition of retinoic acid-inducible gene I-mediated induction of beta interferon by the NS1 protein of influenza A virus. J Virol (2006) 4.88
Newcastle disease virus (NDV)-based assay demonstrates interferon-antagonist activity for the NDV V protein and the Nipah virus V, W, and C proteins. J Virol (2003) 4.45
Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses. J Virol (2005) 4.31
Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science (2013) 4.18
Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J Virol (2006) 3.84
Multiple anti-interferon actions of the influenza A virus NS1 protein. J Virol (2007) 3.53
Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J Virol (2006) 3.50
Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proc Natl Acad Sci U S A (2012) 2.96
Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists. J Virol (2006) 2.78
Inhibition of the type I interferon response by the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus. J Virol (2006) 2.61
Role of ISG15 protease UBP43 (USP18) in innate immunity to viral infection. Nat Med (2004) 2.59
Replication fitness determines high virulence of influenza A virus in mice carrying functional Mx1 resistance gene. Proc Natl Acad Sci U S A (2007) 2.33
Aluminum triflate as a highly active and efficient nonprotic cocatalyst in the palladium-catalyzed methoxycarbonylation reaction. Angew Chem Int Ed Engl (2008) 2.25
Identification of cellular interaction partners of the influenza virus ribonucleoprotein complex and polymerase complex using proteomic-based approaches. J Proteome Res (2007) 2.21
Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes. J Virol (2012) 2.07
Identification of the lymphocytic choriomeningitis virus (LCMV) proteins required to rescue LCMV RNA analogs into LCMV-like particles. J Virol (2002) 1.97
Inhibition of Beta interferon induction by severe acute respiratory syndrome coronavirus suggests a two-step model for activation of interferon regulatory factor 3. J Virol (2005) 1.96
Differential inhibition of type I interferon induction by arenavirus nucleoproteins. J Virol (2007) 1.95
A pan-H1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo. J Virol (2012) 1.90
Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization. J Virol (2010) 1.89
Ube1L and protein ISGylation are not essential for alpha/beta interferon signaling. Mol Cell Biol (2006) 1.80
Recovery of an arenavirus entirely from RNA polymerase I/II-driven cDNA. Proc Natl Acad Sci U S A (2006) 1.79
Lethal mutagenesis of the prototypic arenavirus lymphocytic choriomeningitis virus (LCMV). Virology (2003) 1.76
Transcriptional role of p53 in interferon-mediated antiviral immunity. J Exp Med (2008) 1.72
Role of the virus nucleoprotein in the regulation of lymphocytic choriomeningitis virus transcription and RNA replication. J Virol (2003) 1.69
Influenza B virus NS1-truncated mutants: live-attenuated vaccine approach. J Virol (2008) 1.64
Selective inhibitor of endosomal trafficking pathways exploited by multiple toxins and viruses. Proc Natl Acad Sci U S A (2013) 1.60
In vivo bioluminescent imaging of influenza a virus infection and characterization of novel cross-protective monoclonal antibodies. J Virol (2013) 1.59
Myristoylation of the RING finger Z protein is essential for arenavirus budding. J Virol (2004) 1.58
Characterization of the genomic promoter of the prototypic arenavirus lymphocytic choriomeningitis virus. J Virol (2003) 1.56
The intracellular sites of early replication and budding of SARS-coronavirus. Virology (2007) 1.53
Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Res (2007) 1.53
Crystal structure of the Lassa virus nucleoprotein-RNA complex reveals a gating mechanism for RNA binding. Proc Natl Acad Sci U S A (2011) 1.51
Characterization of the arenavirus RING finger Z protein regions required for Z-mediated inhibition of viral RNA synthesis. J Virol (2002) 1.44
Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis. Proc Natl Acad Sci U S A (2011) 1.42
Recombinant lymphocytic choriomeningitis virus expressing vesicular stomatitis virus glycoprotein. Proc Natl Acad Sci U S A (2003) 1.41
Inhibition of the alpha/beta interferon response by mouse hepatitis virus at multiple levels. J Virol (2007) 1.41
Kinetics of protective antibodies are determined by the viral surface antigen. J Clin Invest (2004) 1.39
Dual role of the lymphocytic choriomeningitis virus intergenic region in transcription termination and virus propagation. J Virol (2005) 1.36
Maternal influenza viral infection causes schizophrenia-like alterations of 5-HT₂A and mGlu₂ receptors in the adult offspring. J Neurosci (2011) 1.36
Modulation of influenza virus replication by alteration of sodium ion transport and protein kinase C activity. Antiviral Res (2008) 1.30
Targeting aberrant glutathione metabolism to eradicate human acute myelogenous leukemia cells. J Biol Chem (2013) 1.25
Host- and strain-specific regulation of influenza virus polymerase activity by interacting cellular proteins. MBio (2011) 1.22
The Ebola virus glycoprotein mediates entry via a non-classical dynamin-dependent macropinocytic pathway. Virology (2011) 1.22
Thogoto virus ML protein suppresses IRF3 function. Virology (2005) 1.19
Uncovering the global host cell requirements for influenza virus replication via RNAi screening. Microbes Infect (2011) 1.19
Nipah virus sequesters inactive STAT1 in the nucleus via a P gene-encoded mechanism. J Virol (2009) 1.18
Protection against lethal influenza with a viral mimic. J Virol (2013) 1.18
Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses. Mol Ther (2009) 1.18
A reverse genetics system for Borna disease virus. J Gen Virol (2003) 1.16
Arenavirus nucleoprotein targets interferon regulatory factor-activating kinase IKKε. J Virol (2012) 1.15
Human cytomegalovirus induces the activity and expression of acetyl-coenzyme A carboxylase, a fatty acid biosynthetic enzyme whose inhibition attenuates viral replication. J Virol (2011) 1.15
Arenavirus nucleoproteins prevent activation of nuclear factor kappa B. J Virol (2012) 1.14
Glycine 184 in nonstructural protein NS1 determines the virulence of influenza A virus strain PR8 without affecting the host interferon response. J Virol (2010) 1.13
The herpes simplex virus 1 US3 protein kinase blocks caspase-dependent double cleavage and activation of the proapoptotic protein BAD. J Virol (2003) 1.13
Metabolite profiles of human immunodeficiency virus infected CD4+ T cells and macrophages using LC-MS/MS analysis. Virology (2011) 1.12
Inhibition of the type I interferon antiviral response during arenavirus infection. Viruses (2010) 1.11
The z protein of the new world arenavirus tacaribe virus has bona fide budding activity that does not depend on known late domain motifs. J Virol (2009) 1.10
Optimization of human immunodeficiency virus type 1 envelope glycoproteins with V1/V2 deleted, using virus evolution. J Virol (2008) 1.10
The carbohydrate at asparagine 386 on HIV-1 gp120 is not essential for protein folding and function but is involved in immune evasion. Retrovirology (2008) 1.10
Mapping the landscape of the lymphocytic choriomeningitis virus stable signal peptide reveals novel functional domains. J Virol (2007) 1.09
Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses. J Virol (2011) 1.09
Crimean-Congo hemorrhagic fever virus delays activation of the innate immune response. J Med Virol (2008) 1.07
Is there a future for antiviral fusion inhibitors? Curr Opin Virol (2012) 1.07
Adjuvants and immunization strategies to induce influenza virus hemagglutinin stalk antibodies. PLoS One (2013) 1.06
Antiviral activity of a small-molecule inhibitor of arenavirus glycoprotein processing by the cellular site 1 protease. J Virol (2010) 1.06
A cell-based phenotypic assay to identify cardioprotective agents. Circ Res (2012) 1.06
Junín virus infection activates the type I interferon pathway in a RIG-I-dependent manner. PLoS Negl Trop Dis (2012) 1.05
Murine coronavirus delays expression of a subset of interferon-stimulated genes. J Virol (2010) 1.05
Strong interferon-inducing capacity of a highly virulent variant of influenza A virus strain PR8 with deletions in the NS1 gene. J Gen Virol (2009) 1.04
Use of single-cycle infectious lymphocytic choriomeningitis virus to study hemorrhagic fever arenaviruses. J Virol (2010) 1.03
Ribavirin can be mutagenic for arenaviruses. J Virol (2011) 1.03
Influenza B virus ribonucleoprotein is a potent activator of the antiviral kinase PKR. PLoS Pathog (2009) 1.03
Influenza A virus attenuation by codon deoptimization of the NS gene for vaccine development. J Virol (2014) 1.02
HCMV targets the metabolic stress response through activation of AMPK whose activity is important for viral replication. PLoS Pathog (2012) 1.02
Inhibition of calmodulin-dependent kinase kinase blocks human cytomegalovirus-induced glycolytic activation and severely attenuates production of viral progeny. J Virol (2010) 1.01
Past, present, and future of arenavirus taxonomy. Arch Virol (2015) 1.00
Nipah virus edits its P gene at high frequency to express the V and W proteins. J Virol (2009) 1.00
Identification of MAVS splicing variants that interfere with RIGI/MAVS pathway signaling. Mol Immunol (2008) 0.99
Recombinant IgA is sufficient to prevent influenza virus transmission in guinea pigs. J Virol (2013) 0.98
Cells expressing the RING finger Z protein are resistant to arenavirus infection. J Virol (2004) 0.98
Crystallographic fragment screening and structure-based optimization yields a new class of influenza endonuclease inhibitors. ACS Chem Biol (2013) 0.98
RNA interference-mediated virus clearance from cells both acutely and chronically infected with the prototypic arenavirus lymphocytic choriomeningitis virus. J Virol (2005) 0.97
A cell-based luciferase assay amenable to high-throughput screening of inhibitors of arenavirus budding. Virology (2008) 0.97
Altered central nervous system gene expression caused by congenitally acquired persistent infection with lymphocytic choriomeningitis virus. J Virol (2006) 0.96
A novel small molecule inhibitor of influenza A viruses that targets polymerase function and indirectly induces interferon. PLoS Pathog (2012) 0.96
Stabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution. J Biol Chem (2010) 0.95
Hypomorphic mutation in the site-1 protease Mbtps1 endows resistance to persistent viral infection in a cell-specific manner. Cell Host Microbe (2011) 0.93
Glycan-dependent immunogenicity of recombinant soluble trimeric hemagglutinin. J Virol (2012) 0.93
Role of the host cell's unfolded protein response in arenavirus infection. J Virol (2010) 0.93
Occluding the mannose moieties on human immunodeficiency virus type 1 gp120 with griffithsin improves the antibody responses to both proteins in mice. AIDS Res Hum Retroviruses (2011) 0.92
A stabilized HIV-1 envelope glycoprotein trimer fused to CD40 ligand targets and activates dendritic cells. Retrovirology (2011) 0.92